Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus crizotinib in crizotinib-resistant NSCLC
ChiCTR-OIC-17013276Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and crizotinib in non-small cell lung cancer (NSCLC), sponsored by Shanxi Cancer Hospital. Primary endpoint: Progression-free survival. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OIC-17013276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013276.